

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044793 A3(51) International Patent Classification⁷: **A61K 31/44**,
31/415, C07D 471/02, 235/04(21) International Application Number:
PCT/US2004/035648

(22) International Filing Date: 27 October 2004 (27.10.2004)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
60/516,164 31 October 2003 (31.10.2003) US
60/560,518 8 April 2004 (08.04.2004) US(71) Applicant (for all designated States except US): **TAKEDA
PHARMACEUTICAL COMPANY LIMITED [JP/JP]**;
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka
541-0045 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GYORKOS,
Albert, Charles [US/US]**; 11795 Decatur Drive, West-
minster, CO 80234 (US). **CORRETTE, Christopher,
Peter [US/US]**; 13839 W. 66th Way, Arvada, CO 80004(US). **CHO, Suk, Young [US/US]**; 1091 Button Rock
Drive, Longmont, CO 80501 (US). **TURNER, Timothy,
Mark [US/US]**; 1028 Morning Dove Drive, Long-
mont, CO 80501 (US). **PRATT, Scott, Alan [US/US]**;
11713 Victor Drive, Longmont, CO 80504 (US). **ASO,
Kazuyoshi [JP/JP]**; 10-5-307, Kamihamuro 1-chome,
Takatsuki-shi, Osaka 569-1044 (JP). **KORI, Masakuni
[JP/JP]**; 15-7, Takenodai 5-chome, Nishi-ku, Kobe-shi,
Hyogo 651-2274 (JP). **GYOTEN, Michiyo [JP/JP]**; 2727
Nelson Road, #H-207, Longmont, CO 80503 (JP).(74) Agents: **CHAO, Mark et al.**; Takeda Pharmaceuticals
North America, Inc., 475 Half-day Road, Lincolnshire, IL
60069 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

[Continued on next page]

(54) Title: NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS



(57) Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X¹ is an oxygen, a sulfur or -NR⁵-, or formula (A''): wherein X is a nitrogen and R⁶ is an optionally substituted hydrocarbyl, R¹ is an amino substituted by two optionally substituted hydrocarbyl groups, R² is an phenyl, Y¹ is CR^{3a} or a nitrogen, Y² is CR^{3b} or a nitrogen and Y³ is CR^{3c} or a nitrogen, provided that one or less of Y¹, Y², and Y³ is nitrogen, W is a bond, -(CH₂)_n-, and Z is a bond, -NR⁴-, etc.; or a salt thereof or a prodrug thereof.

